Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo, the Japan-based pharmaceutical company, has launched Rezaltas combination tablets LD and HD for the treatment of hypertension in Japan.
Subscribe to our email newsletter
Rezaltas is a combination drug featuring the Daiichi Sankyo-developed olmesartan medoxomil (Olmetec), a high-affinity ARB (angiotensin receptor blocker) and azelnidipine (Calblock), a long-acting CCB (calcium channel blocker) that the company researched and developed with Ube
Industries.
Daiichi Sankyo has claimed that it has combined olmesartan medoxomil, which has proven exceptionally powerful in lowering blood pressure among ARBs, with azelnidipine, a CCB that delivers ongoing decreases in blood pressure while minimizing sympathomimetic hyperactivity.
Daiichi Sankyo said that the clinical studies demonstrated that Rezaltas consistently suppresses blood pressure for 24 hours while offering excellent tolerance.